{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:28:37Z","timestamp":1768462117449,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.4065\/81.8.1047","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:27:47Z","timestamp":1232760467000},"page":"1047-1053","source":"Crossref","is-referenced-by-count":192,"title":["Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma"],"prefix":"10.4065","volume":"81","author":[{"given":"Martha Q.","family":"Lacy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly L.","family":"Gollbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Zeldenrust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Lief","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan B.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kademani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene E.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher F.","family":"Viozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/81.8.1047_bib1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.beha.2005.01.008","article-title":"Multiple myeloma: clinical features and indications for therapy","volume":"18","author":"Dispenzieri","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.4065\/81.8.1047_bib2","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"key":"10.4065\/81.8.1047_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11, pt 1","key":"10.4065\/81.8.1047_bib4","first-page":"167a","article-title":"Thalidomide with dexamethasone for resistant multiple myeloma [abstract]","volume":"96","author":"Weber","year":"2000","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/81.8.1047_bib5","first-page":"168a","article-title":"Durable response to thalidomide in relapsed\/refractory multiple myeloma (MM)","volume":"96","author":"Raza","year":"2000","journal-title":"Blood"},{"key":"10.4065\/81.8.1047_bib6","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.8.1047_bib7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V93.1.300","article-title":"Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"93","author":"Lacy","year":"1999","journal-title":"Blood"},{"key":"10.4065\/81.8.1047_bib8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0889-8588(05)70115-5","article-title":"The role of interleukin-1 beta in the pathogenesis of multiple myeloma","volume":"13","author":"Lust","year":"1999","journal-title":"Hemat Oncol Clin North Am"},{"key":"10.4065\/81.8.1047_bib9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","article-title":"Interleukin-6 in human multiple myeloma","volume":"85","author":"Klein","year":"1995","journal-title":"Blood"},{"key":"10.4065\/81.8.1047_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0037-1963(01)90020-4","article-title":"Myeloma bone disease","volume":"38","author":"Callander","year":"2001","journal-title":"Semin Hematol"},{"key":"10.4065\/81.8.1047_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2141.1990.tb06330.x","article-title":"The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma","volume":"74","author":"Carter","year":"1990","journal-title":"Br J Haematol"},{"issue":"suppl 2","key":"10.4065\/81.8.1047_bib12","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1007\/s00586-003-0622-z","article-title":"Bisphosphonates in osteoporosis","volume":"12","author":"Fleisch","year":"2003","journal-title":"Eur Spine J"},{"key":"10.4065\/81.8.1047_bib13","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases [published correction appears in Cancer. 2001;91:1956]","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.4065\/81.8.1047_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4065\/81.8.1047_bib15","first-page":"478","article-title":"A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases","volume":"7","author":"Berenson","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.4065\/81.8.1047_bib16","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.4065\/81.8.1047_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.4065\/81.8.1047_bib18","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma [published correction appears in Lancet. 1992;340:1420]","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.4065\/81.8.1047_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.4065\/81.8.1047_bib20","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.8.1047_bib21","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","article-title":"Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years","volume":"10","author":"Guarneri","year":"2005","journal-title":"Oncologist"},{"key":"10.4065\/81.8.1047_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000080996","article-title":"Safety of long-term administration of bisphosphonates in elderly cancer patients","volume":"67","author":"Tralongo","year":"2004","journal-title":"Oncology"},{"key":"10.4065\/81.8.1047_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1634\/theoncologist.9-3-319","article-title":"Safety and convenience of a 15-minute infusion of zoledronic acid","volume":"9","author":"Berenson","year":"2004","journal-title":"Oncologist"},{"key":"10.4065\/81.8.1047_bib24","first-page":"478","article-title":"Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience)","volume":"59","author":"Kraj","year":"2002","journal-title":"Acta Pol Pharm"},{"key":"10.4065\/81.8.1047_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4065\/78.1.118","article-title":"Use of bisphosphonates in patients with myeloma and renal failure [letter and reply]","volume":"78","author":"Saghafi","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.8.1047_bib26","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"2, suppl 6","key":"10.4065\/81.8.1047_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/sonc.2001.24157","article-title":"Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials","volume":"28","author":"Berenson","year":"2001","journal-title":"Semin Oncol"},{"issue":"suppl 1","key":"10.4065\/81.8.1047_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","article-title":"Preclinical perspectives on bisphosphonate renal safety","volume":"10","author":"Body","year":"2005","journal-title":"Oncologist"},{"key":"10.4065\/81.8.1047_bib29","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.4065\/81.8.1047_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","author":"Conte","year":"2004","journal-title":"Oncologist"},{"issue":"suppl 4","key":"10.4065\/81.8.1047_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.4065\/81.8.1047_bib32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic [letter]","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.4065\/81.8.1047_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates [letter]","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4065\/81.8.1047_bib34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0714.2004.00269.x","article-title":"Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases","volume":"34","author":"Bagan","year":"2005","journal-title":"J Oral Pathol Med"},{"key":"10.4065\/81.8.1047_bib35","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.14219\/jada.archive.2005.0110","article-title":"Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition","volume":"136","author":"Melo","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"10.4065\/81.8.1047_bib36","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2141.2005.05382.x","article-title":"Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma","volume":"128","author":"Vannucchi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.4065\/81.8.1047_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"key":"10.4065\/81.8.1047_bib38","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper [published correction appears in J Am Dent Assoc. 2006;137:26]","volume":"136","author":"Migliorati","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"10.4065\/81.8.1047_bib39","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.8.1047_bib40","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.8.1047_bib41","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","article-title":"Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment","volume":"32","author":"Ficarra","year":"2005","journal-title":"J Clin Periodontol"},{"key":"10.4065\/81.8.1047_bib42","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.4065\/81.8.1047_bib43","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.4065\/81.8.1100","article-title":"Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy","volume":"81","author":"Kademani","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.8.1047_bib44","first-page":"408","article-title":"The causation of phosphorus necrosis","volume":"2","author":"Dearden","year":"1901","journal-title":"BMJ"},{"key":"10.4065\/81.8.1047_bib45","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/bmj.2.2013.270-a","article-title":"Fragilitas ossium amongst workers in Lucifer match factories","volume":"2","author":"Dearden","year":"1899","journal-title":"BMJ"},{"key":"10.4065\/81.8.1047_bib46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bdj.4802906","article-title":"Phosphorus necrosis of the jaw: \u2018phossy jaw\u2019","volume":"133","author":"Miles","year":"1972","journal-title":"Br Dent J"},{"key":"10.4065\/81.8.1047_bib47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0278-2391(83)90294-X","article-title":"Osteoradionecrosis: a new concept of its pathophysiology","volume":"41","author":"Marx","year":"1983","journal-title":"J Oral Maxillofac Surg"},{"key":"10.4065\/81.8.1047_bib48","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.4065\/81.8.1047_bib49","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/annonc\/mdg401","article-title":"The antineoplastic role of bisphosphonates: from basic research to clinical evidence","volume":"14","author":"Santini","year":"2003","journal-title":"Ann Oncol"},{"key":"10.4065\/81.8.1047_bib50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.oraloncology.2005.08.001","article-title":"Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions: study of 20 cases [letter]","volume":"42","author":"Bagan","year":"2006","journal-title":"Oral Oncol"},{"key":"10.4065\/81.8.1047_bib51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates\u2014histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen","year":"2006","journal-title":"J Oral Pathol Med"},{"issue":"suppl 2","key":"10.4065\/81.8.1047_bib52","first-page":"E88","article-title":"Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update","volume":"10","author":"Jimenez-Soriano","year":"2005","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.4065\/81.8.1047_bib53","first-page":"100","article-title":"Osteonecrosis of the jaw and bisphosphonates [letter] [published correction appears in N Engl J Med. 2005;353: 2728]","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4065\/81.8.1047_bib54","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.4065\/81.8.1047_bib55","first-page":"E76","article-title":"Osteonecrosis of the jaws and bisphosphonates: report of three cases","volume":"11","author":"Pastor-Zuazaga","year":"2006","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.4065\/81.8.1047_bib56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ajh.20481","article-title":"Osteonecrosis of the jaw associated with pamidronate therapy","volume":"81","author":"Zarychanski","year":"2006","journal-title":"Am J Hematol"},{"key":"10.4065\/81.8.1047_bib57","doi-asserted-by":"crossref","first-page":"335a","DOI":"10.1182\/blood.V106.11.1148.1148","article-title":"Maintenance treatment with thalidomide after autologous transplantation for myeloma: final analysis of a prospective randomized study of the \u201cIntergroupe Francophone du Myelome\u201d [abstract]","volume":"106","author":"Attal","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.8.1047_bib58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00003495-199142060-00003","article-title":"Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease","volume":"42","author":"Fleisch","year":"1991","journal-title":"Drugs"},{"key":"10.4065\/81.8.1047_bib59","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","article-title":"Markers of bone resorption in patients treated with pamidronate","volume":"34","author":"Lipton","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.4065\/81.8.1047_bib60","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1600-0609.2000.065005331.x","article-title":"Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma","volume":"65","author":"Terpos","year":"2000","journal-title":"Eur J Haematol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611612068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611612068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T14:02:40Z","timestamp":1633010560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611612068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0025619611612068"],"URL":"https:\/\/doi.org\/10.4065\/81.8.1047","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}